Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

AYTU vs PRGO vs TEVA vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AYTU
Aytu BioPharma, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$16M
5Y Perf.-99.2%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-78.6%
TEVA
Teva Pharmaceutical Industries Limited

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IL
Market Cap$41.93B
5Y Perf.+187.4%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+374.1%

AYTU vs PRGO vs TEVA vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AYTU logoAYTU
PRGO logoPRGO
TEVA logoTEVA
MCK logoMCK
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericMedical - Distribution
Market Cap$16M$1.61B$41.93B$92.15B
Revenue (TTM)$63M$4.18B$17.35B$403.43B
Net Income (TTM)$-24M$-1.82B$1.56B$4.76B
Gross Margin66.0%34.2%52.1%3.6%
Operating Margin-13.9%-4.1%13.2%1.5%
Forward P/E5.6x14.5x19.3x
Total Debt$23M$3.97B$17.38B$7.39B
Cash & Equiv.$31M$532M$3.56B$5.69B

AYTU vs PRGO vs TEVA vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AYTU
PRGO
TEVA
MCK
StockMay 20May 26Return
Aytu BioPharma, Inc. (AYTU)1000.8-99.2%
Perrigo Company plc (PRGO)10021.4-78.6%
Teva Pharmaceutical… (TEVA)100287.4+187.4%
McKesson Corporation (MCK)100474.1+374.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: AYTU vs PRGO vs TEVA vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCK leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. TEVA also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
AYTU
Aytu BioPharma, Inc.
The Secondary Option

AYTU lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
PRGO
Perrigo Company plc
The Defensive Pick

PRGO is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.

  • Lower volatility, beta 1.18, current ratio 2.76x
  • Beta 1.18, yield 9.8%, current ratio 2.76x
  • Lower P/E (5.6x vs 19.3x)
  • 9.8% yield, 10-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
Best for: sleep-well-at-night and defensive
TEVA
Teva Pharmaceutical Industries Limited
The Quality Compounder

TEVA is the clearest fit if your priority is quality and momentum.

  • 9.0% margin vs PRGO's -43.5%
  • +104.6% vs PRGO's -51.2%
Best for: quality and momentum
MCK
McKesson Corporation
The Income Pick

MCK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 17 yrs, beta 0.04, yield 0.4%
  • Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
  • 348.1% 10Y total return vs TEVA's -28.3%
  • 16.2% revenue growth vs PRGO's -2.8%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK16.2% revenue growth vs PRGO's -2.8%
ValuePRGO logoPRGOLower P/E (5.6x vs 19.3x)
Quality / MarginsTEVA logoTEVA9.0% margin vs PRGO's -43.5%
Stability / SafetyMCK logoMCKBeta 0.04 vs AYTU's 1.27
DividendsPRGO logoPRGO9.8% yield, 10-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
Momentum (1Y)TEVA logoTEVA+104.6% vs PRGO's -51.2%
Efficiency (ROA)MCK logoMCK5.7% ROA vs AYTU's -20.0%, ROIC 5.4% vs -33.5%

AYTU vs PRGO vs TEVA vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

AYTUAytu BioPharma, Inc.
FY 2024
Consumer Health
100.0%$16M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
TEVATeva Pharmaceutical Industries Limited
FY 2025
Product
84.6%$14.6B
Distribution Service
9.0%$1.6B
License
3.9%$678M
Product and Service, Other
2.5%$423M
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

AYTU vs PRGO vs TEVA vs MCK — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLTEVALAGGINGAYTU

Income & Cash Flow (Last 12 Months)

TEVA leads this category, winning 4 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 6440.5x AYTU's $63M. TEVA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, MCK holds the edge at +6.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricAYTU logoAYTUAytu BioPharma, I…PRGO logoPRGOPerrigo Company p…TEVA logoTEVATeva Pharmaceutic…MCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$63M$4.2B$17.3B$403.4B
EBITDAEarnings before interest/tax-$4M$58M$3.3B$6.8B
Net IncomeAfter-tax profit-$24M-$1.8B$1.6B$4.8B
Free Cash FlowCash after capex-$698,000$108M$1.2B$6.0B
Gross MarginGross profit ÷ Revenue+66.0%+34.2%+52.1%+3.6%
Operating MarginEBIT ÷ Revenue-13.9%-4.1%+13.2%+1.5%
Net MarginNet income ÷ Revenue-39.0%-43.5%+9.0%+1.2%
FCF MarginFCF ÷ Revenue-1.1%+2.6%+6.8%+1.5%
Rev. Growth (YoY)Latest quarter vs prior year-6.5%-7.2%+2.3%+6.0%
EPS Growth (YoY)Latest quarter vs prior year-3.0%-56.4%+72.2%+37.0%
TEVA leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 4 of 6 comparable metrics.

At 29.2x trailing earnings, MCK trades at a 3% valuation discount to TEVA's 30.0x P/E. On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than MCK's 18.7x.

MetricAYTU logoAYTUAytu BioPharma, I…PRGO logoPRGOPerrigo Company p…TEVA logoTEVATeva Pharmaceutic…MCK logoMCKMcKesson Corporat…
Market CapShares × price$16M$1.6B$41.9B$92.1B
Enterprise ValueMkt cap + debt − cash$7M$5.1B$55.8B$93.8B
Trailing P/EPrice ÷ TTM EPS-1.14x-1.14x30.01x29.25x
Forward P/EPrice ÷ next-FY EPS est.5.56x14.55x19.28x
PEG RatioP/E ÷ EPS growth rate0.75x
EV / EBITDAEnterprise value multiple7.42x17.65x18.74x
Price / SalesMarket cap ÷ Revenue0.23x0.38x2.43x0.26x
Price / BookPrice ÷ Book value/share0.82x0.55x5.34x
Price / FCFMarket cap ÷ FCF11.12x36.52x17.63x
PRGO leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 5 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-172 for AYTU. AYTU carries lower financial leverage with a 1.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x. On the Piotroski fundamental quality scale (0–9), TEVA scores 8/9 vs AYTU's 3/9, reflecting strong financial health.

MetricAYTU logoAYTUAytu BioPharma, I…PRGO logoPRGOPerrigo Company p…TEVA logoTEVATeva Pharmaceutic…MCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity-172.1%-50.7%+20.7%+3.0%
ROA (TTM)Return on assets-20.0%-19.8%+3.9%+5.7%
ROICReturn on invested capital-33.5%+3.7%+7.7%+5.4%
ROCEReturn on capital employed-13.3%+4.3%+8.0%+30.5%
Piotroski ScoreFundamental quality 0–93486
Debt / EquityFinancial leverage1.21x1.35x2.20x
Net DebtTotal debt minus cash-$8M$3.4B$13.8B$1.7B
Cash & Equiv.Liquid assets$31M$532M$3.6B$5.7B
Total DebtShort + long-term debt$23M$4.0B$17.4B$7.4B
Interest CoverageEBIT ÷ Interest expense-7.96x-7.20x2.51x33.79x
MCK leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TEVA leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $215 for AYTU. Over the past 12 months, TEVA leads with a +104.6% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.4% vs PRGO's -25.2% — a key indicator of consistent wealth creation.

MetricAYTU logoAYTUAytu BioPharma, I…PRGO logoPRGOPerrigo Company p…TEVA logoTEVATeva Pharmaceutic…MCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date-10.8%-13.5%+16.3%-8.5%
1-Year ReturnPast 12 months+104.1%-51.2%+104.6%+4.6%
3-Year ReturnCumulative with dividends+40.3%-58.1%+297.5%+106.4%
5-Year ReturnCumulative with dividends-97.8%-60.1%+246.2%+286.9%
10-Year ReturnCumulative with dividends-100.0%-77.7%-28.3%+348.1%
CAGR (3Y)Annualised 3-year return+12.0%-25.2%+58.4%+27.3%
TEVA leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — TEVA and MCK each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than AYTU's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TEVA currently trades 96.4% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAYTU logoAYTUAytu BioPharma, I…PRGO logoPRGOPerrigo Company p…TEVA logoTEVATeva Pharmaceutic…MCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5001.27x1.18x1.13x0.04x
52-Week HighHighest price in past year$3.07$28.44$37.35$999.00
52-Week LowLowest price in past year$1.20$9.23$14.99$637.00
% of 52W HighCurrent price vs 52-week peak+80.5%+41.2%+96.4%+75.3%
RSI (14)Momentum oscillator 0–10048.960.973.516.2
Avg Volume (50D)Average daily shares traded42K3.4M6.6M757K
Evenly matched — TEVA and MCK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.

Analyst consensus: PRGO as "Hold", TEVA as "Buy", MCK as "Buy". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 8.3% for TEVA (target: $39). For income investors, PRGO offers the higher dividend yield at 9.81% vs MCK's 0.36%.

MetricAYTU logoAYTUAytu BioPharma, I…PRGO logoPRGOPerrigo Company p…TEVA logoTEVATeva Pharmaceutic…MCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellHoldBuyBuy
Price TargetConsensus 12-month target$20.00$39.00$1006.50
# AnalystsCovering analysts364631
Dividend YieldAnnual dividend ÷ price+9.8%+0.4%
Dividend StreakConsecutive years of raises10117
Dividend / ShareAnnual DPS$1.15$2.69
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+3.4%
Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.
Key Takeaway

TEVA leads in 2 of 6 categories (Income & Cash Flow, Total Returns). PRGO leads in 1 (Valuation Metrics). 2 tied.

Best OverallTeva Pharmaceutical Industr… (TEVA)Leads 2 of 6 categories
Loading custom metrics...

AYTU vs PRGO vs TEVA vs MCK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is AYTU or PRGO or TEVA or MCK a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). McKesson Corporation (MCK) offers the better valuation at 29. 2x trailing P/E (19. 3x forward), making it the more compelling value choice. Analysts rate Teva Pharmaceutical Industries Limited (TEVA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — AYTU or PRGO or TEVA or MCK?

On trailing P/E, McKesson Corporation (MCK) is the cheapest at 29.

2x versus Teva Pharmaceutical Industries Limited at 30. 0x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — AYTU or PRGO or TEVA or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -97. 8% for Aytu BioPharma, Inc. (AYTU). Over 10 years, the gap is even starker: MCK returned +348. 1% versus AYTU's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — AYTU or PRGO or TEVA or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Aytu BioPharma, Inc. 's 1. 27β — meaning AYTU is approximately 2858% more volatile than MCK relative to the S&P 500. On balance sheet safety, Aytu BioPharma, Inc. (AYTU) carries a lower debt/equity ratio of 121% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — AYTU or PRGO or TEVA or MCK?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — AYTU or PRGO or TEVA or MCK?

Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.

2% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TEVA leads at 12. 5% versus -11. 8% for AYTU. At the gross margin level — before operating expenses — AYTU leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is AYTU or PRGO or TEVA or MCK more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 19. 3x for McKesson Corporation — 13. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

08

Which pays a better dividend — AYTU or PRGO or TEVA or MCK?

In this comparison, PRGO (9.

8% yield), MCK (0. 4% yield) pay a dividend. AYTU, TEVA do not pay a meaningful dividend and should not be held primarily for income.

09

Is AYTU or PRGO or TEVA or MCK better for a retirement portfolio?

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +348. 1% 10Y return). Both have compounded well over 10 years (MCK: +348. 1%, AYTU: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between AYTU and PRGO and TEVA and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AYTU is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; TEVA is a mid-cap quality compounder stock; MCK is a mid-cap high-growth stock. PRGO pays a dividend while AYTU, TEVA, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

AYTU

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 39%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

TEVA

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform AYTU and PRGO and TEVA and MCK on the metrics below

Revenue Growth>
%
(AYTU: -6.5% · PRGO: -7.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.